BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 04, 2002
 |  BioCentury  |  Strategy

Xoma phaging into discovery

Xoma Ltd. believes that a commanding intellectual property position in the bacterial expression of antibodies has given it the leverage to integrate back into the development space, reflected by its licensing deal last week with phage display specialist MorphoSys AG.

"This deal gives us a baseline to work from for our deals with the other phage display companies. We have a number of patents that all the phage display companies are infringing," XOMA CEO Jack Castello told BioCentury. "These are basic patents that are required for them to operate."

Indeed, XOMA currently is embroiled in litigation with its first licensee, Biosite Inc. (BSTE, San Diego, Calif.), which XOMA alleges has breached the original agreements reached in 1998 and 1999 (see BioCentury, June 11, 2001 &...

Read the full 618 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >